00:12 , Jun 15, 2019 |  BC Extra  |  Company News

June 13 Company Quick Takes: ISS rebuffs Takeda’s Weber; plus Sage, Blueprint, Tetraphase, Celgene and more

ISS weighs in on Weber  Institutional Shareholder Services recommended Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) shareholders oppose President and CEO Christophe Weber at the June 27 shareholder meeting because “top management is responsible for the...
23:45 , May 9, 2019 |  BC Extra  |  Company News

May 9 Company Quick Takes: Chimerix, Puma, Janssen

Chimerix abandons brincidofovir trials  Chimerix Inc. (NASDAQ:CMRX) will cut its workforce in half after deciding to discontinue all clinical trials of adenovirus candidate brincidofovir due to low patient recruitment, five years after access to the...
23:55 , Mar 14, 2019 |  BC Week In Review  |  Company News

AbCellera, Gates Foundation partner on infectious disease treatments

Antibody company AbCellera partnered with the Bill & Melinda Gates Foundation to develop vaccines and antibody-based therapies to treat infectious diseases. AbCellera Biologics Inc. (Vancouver, B.C.) will receive $4.8 million in funding for the two-year...
17:29 , Mar 8, 2019 |  BC Week In Review  |  Company News

AbCellera, Denali to discover neurological disease antibodies

AbCellera will generate panels of antibodies against up to eight neurology targets selected by Denali using AbCellera’s high-throughput, ultra-deep single-cell immune profiling platform. Denali Therapeutics Inc. (NASDAQ:DNLI) will pay a technology access fee and research...
18:10 , Feb 15, 2019 |  BC Week In Review  |  Company News

AbCellera, Novartis partner on antibody discovery

AbCellera Biologics Inc. (Vancouver, B.C.) will use its single cell screening platform to discover antibodies against 10 undisclosed targets chosen by Novartis AG (NYSE:NVS; SIX:NOVN). AbCellera CEO Carl Hansen told BioCentury the company expects to...
20:30 , Jun 16, 2017 |  BC Week In Review  |  Company News

AbCellera, Teva to discover antibodies targeting undisclosed membrane protein

AbCellera Biologics Inc. (Vancouver, B.C.) will use its antibody screening platform to discover antibodies that modulate the function of an undisclosed membrane protein target selected by Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA). AbCellera will...
19:54 , Jan 13, 2017 |  BC Week In Review  |  Company News

AbCellera, Pfizer deal

AbCellera will use its high-throughput single cell antibody platform to discover function-modulating antibodies against multiple undisclosed membrane protein targets. The company will receive an undisclosed upfront payment and research support and is be eligible for...
08:00 , Feb 22, 2016 |  BC Week In Review  |  Company News

Teva, AbCellera deal

AbCellera will use its high-throughput single cell antibody platform to discover mAbs. AbCellera will receive an undisclosed upfront payment and R&D milestones. Teva did not respond to inquiries, and AbCellera declined to disclose additional details....
08:00 , Feb 8, 2016 |  BC Week In Review  |  Company News

AbCellera, Merck deal

AbCellera and Merck will use AbCellera’s microfluidic discovery technology to discover mAbs against an undisclosed target. Merck has the option to develop antibody candidates generated under the deal. The partners declined to provide additional details....